搜索临床试验以:High Risk Rectal Cancer
总计111335个结果
-
Aptose Biosciences Inc.University of Chicago; Wake Forest University完全的
-
Hebrew University of JerusalemAnchiano Therapeutics Israel Ltd.完全的
-
Celtic Pharma Development ServicesNeurobiological Technologies撤销
-
Massachusetts General HospitalEli Lilly and Company; GlaxoSmithKline完全的
-
Astellas Pharma Inc完全的
-
University of California, Davis完全的
-
The Netherlands Cancer InstituteDutch Cancer Society未知因治疗引起的主诉的乳腺癌患者的更年期症状
-
University Hospital, Ghent完全的
-
National Institute of Arthritis and Musculoskeletal...University of Pittsburgh; Genzyme, a Sanofi Company; Amgen终止
-
Dana-Farber Cancer InstituteBrigham and Women's Hospital完全的
-
Maxygen Holdings Ltd.Parexel; Maxygen ApS; Maxygen, Inc.未知
-
Cell Genesys完全的
-
Cell Genesys完全的
-
Amgen完全的
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital完全的
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Brigham and Women's Hospital完全的
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Eli Lilly and Company; Beth Israel Deaconess Medical Center; Brigham...完全的
-
Hadassah Medical Organization未知Female Patients Aged 5-35 Prior to Systemic Chemotherapy | With Significant Risk of Ovarian Toxicity以色列
-
Dana-Farber Cancer InstituteNovartis; Brigham and Women's Hospital完全的
-
Callisto Pharmaceuticals完全的
-
Fred Hutchinson Cancer CenterNational Institutes of Health (NIH); Burroughs Wellcome完全的
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital 和其他合作者完全的
-
Eli Lilly and Company完全的癌,非小细胞肺癌荷兰, 西班牙, 美国, 加拿大, 以色列, 德国
-
Stanford UniversityMedtronic完全的